Tackling the hidden CV and kidney dangers in T2D with SGLT2 inhibitors

Education provider – Science Collected. Supported by an unrestricted educational grant from AstraZeneca. |

16:00 – 16:05Welcome and Introductions
16:05 – 16:20Looking beyond T2D – The heart and kidney
16:20 – 16:40Don’t wait to protect the kidneys
16:40 – 16:50Let’s not forget about the heart
16:50 – 17:00We are all in this together
17:00 – 17:25Panel discussion and Q&A
17:25 – 17:30Closing remarks


  • Recognize the high risk of CKD and HF in patients with T2D and understand the importance of identifying comorbid patients to improve patient outcomes
  • Understand how recent SGLT2 inhibitor efficacy and safety data shaped guideline recommendations on early protection for patients with T2D and CKD or HF
  • Identify opportunities to drive integrated care and ensure patients are managed early for optimal CV and kidney protection

Education provider

Supported by an unrestricted educational grant from